Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes.

Autor: Jindal S; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Pennock ND; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Sun D; Computational Biology Program, Oregon Health & Science University, Portland, OR, USA., Horton W; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA.; Computational Biology Program, Oregon Health & Science University, Portland, OR, USA., Ozaki MK; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Narasimhan J; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Bartlett AQ; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Weinmann S; Center for Health Research, Kaiser Permanente Northwest, 3800N. Interstate Ave., Portland, OR, USA., Goss PE; Massachusetts General Hospital Cancer Center, Harvard University, Boston, MA, USA., Borges VF; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO, USA., Xia Z; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Computational Biology Program, Oregon Health & Science University, Portland, OR, USA.; Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, USA., Schedin P; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA. schedin@ohsu.edu.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. schedin@ohsu.edu.; Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO, USA. schedin@ohsu.edu.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2021 Nov 03; Vol. 12 (1), pp. 6341. Date of Electronic Publication: 2021 Nov 03.
DOI: 10.1038/s41467-021-26505-3
Abstrakt: Young women's breast cancer (YWBC) has poor prognosis and known interactions with parity. Women diagnosed within 5-10 years of childbirth, defined as postpartum breast cancer (PPBC), have poorer prognosis compared to age, stage, and biologic subtype-matched nulliparous patients. Genomic differences that explain this poor prognosis remain unknown. In this study, using RNA expression data from clinically matched estrogen receptor positive (ER+) cases (n = 16), we observe that ER+ YWBC can be differentiated based on a postpartum or nulliparous diagnosis. The gene expression signatures of PPBC are consistent with increased cell cycle, T-cell activation and reduced estrogen receptor and TP53 signaling. When applied to a large YWBC cohort, these signatures for ER+ PPBC associate with significantly reduced 15-year survival rates in high compared to low expressing cases. Cumulatively these results provide evidence that PPBC is a unique entity within YWBC with poor prognostic phenotypes.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: